Mode
Text Size
Log in / Sign up
N/A N=1,391 Randomized Treatment

HIV Treatment Retention Interventions for Women Living With HIV (Siyaphambili Study)

HIV-1 Virologic Response

Enrolled (actual)
1,391
Serious AEs
1.8%
Results posted
Sep 2023
Primary outcome: Primary: Percentage of Participants Retained and Virally Suppressed Among Those Receiving the DTP Versus ICM Arms — 16.0; 14.1 percentage of participants — p=0.455

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
DTP (Behavioral); ICM (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Johns Hopkins Bloomberg School of Public Health
Primary completion
Nov 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants Retained and Virally Suppressed Among Those Receiving the DTP Versus ICM Arms
16.0; 14.1 0.455
SECONDARY
Retention and Viral Suppression of Non-Responders
11.4; 11.3 0.962
SECONDARY
Risk Factors of Loss to Follow-up
87; 36; 159; 40; 227; 66 <0.05 sig
SECONDARY
Durability of Retention and Viral Suppression of Responders
43.1; 40.0 0.756
SECONDARY
Adherence Assessment
46.5; 51.6 0.295
SECONDARY
Viral Suppression of Retained
29.0; 23.0 0.149
SECONDARY
Loss-to-Follow-Up
45.0; 41.3 0.301
SECONDARY
Intervention Acceptability
163; 156
SECONDARY
2nd/3rd Line ART
36; 32
SECONDARY
ART Resistance
37; 34 0.212
SECONDARY
Participants' Costs South in African Rand (ZAR)
186.8; 164.9; 127.7; 256.1

Summary

The Siyaphambili Study is a sequential multistage adaptive randomized trial (SMART) to compare the effectiveness and durability of two behavioral interventions on the HIV-1 virologic response among female sex workers (FSW) living with HIV in Durban, South Africa. The interventions are: 1) nurse-led decentralized treatment program (DTP) and 2) individualized case management (ICM). Viral suppression is defined as a viral load assessment <50 RNA copies/mL. The design will also estimate the incremental cost-effectiveness of study interventions and combinations of interventions compared with maintaining the South African standard of HIV care and treatment.

Eligibility Criteria

Inclusion Criteria

  • Sells sex for goods or money as their main source of income
  • Assigned female sex at birth
  • ≥ 18 years of age
  • Living with HIV; diagnosed ≥ 6 months prior
  • Currently living in Durban
  • If on ART, initiated ≥2 months prior

Exclusion Criteria

  • Engagement in an ongoing HIV treatment research study
  • Planning on leaving Durban for more than 3 months in the following 12 months
  • Pregnant at time of enrollment
  • On a second line or third ART regimen
  • Participating in an adherence club
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03500172). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search